FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/08/2025
Back to search
Official data from USPTO
MABCALIN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
MABCALIN
ST13
US500000079361821Class
1, 5, 42
Filing
79361821
Registration
7459076
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
04/03/2026
Trademark type
Word
Nice classes
1, 5, 42
Filing date
12/19/2022
Registration date
07/30/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/30/2024
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
27
Owner location
DE
Examiner
RIRIE, VERNA BETH
Law office
L40
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Pieris Pharmaceuticals GmbH
Representatives
Michael J. Leonard Fox Rothschild LLP
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical preparations for industrial and scientific purposes; polypeptides and proteins produced by genetic engineering and nucleic acids produced through genetic coding for use in scientific research; diagnostic preparationsother than for medical or veterinary purposes
Class 5
Pharmaceuticalveterinary and sanitary preparationsartificial polypeptides and proteins and nucleic acids produced through genetic coding for the treatment or prevention of various types of cancers and autoimmune diseases; diagnostic reagents for medical or veterinary usein particular for the diagnosis of various types of cancers and autoimmune diseases
Class 42
Scientific and industrial researchin particular in the biochemicaldiagnostic or pharmaceutical fields; laboratory research services relating to biochemical and pharmaceuticals
Publications
History of USPTO decisions and trademark events.
25 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/22/2025
FIMP
FINAL DISPOSITION PROCESSED
01/22/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/30/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
08/03/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/30/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
07/30/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/12/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
07/12/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/14/2024
PUBO
PUBLISHED FOR OPPOSITION
05/14/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/24/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/08/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/08/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/08/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/08/2024
RFNT
REFUSAL PROCESSED BY IB
11/07/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
10/16/2023
RFRR
REFUSAL PROCESSED BY MPU
10/16/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/01/2023
CNRT
NON-FINAL ACTION WRITTEN
09/30/2023
DOCK
ASSIGNED TO EXAMINER
09/20/2023
MAFR
APPLICATION FILING RECEIPT MAILED
02/10/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/06/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/03/2023
Continuous trademark protection
Get notified about every new filing that threatens MABCALIN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.